This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
While several therapeutics are available for treating symptoms associated with epilepsy, researchers and patients have strongly called out the need for more holistic treatments that would address the condition as a whole. Meanwhile, others are researching the link between gene variation and different responses to treatments.
David Del Bourgo (CEO and co-founder, Whitelab Genomics) has always been passionate about introducing disruptive, innovative technologies to markets. We founded Whitelab Genomics after realising the potential to use data, data science, and AI in a more systematic way to develop genomic therapies,” Del Bourgo says.
This “lossiness” largely preserves the image while vastly reducing its file size — and serves as the inspiration for a new research direction in genomics, according to Justin Pritchard, assistant professor of biomedical engineering. […].
Saying genetics researchers inconsistently and inappropriately use racial and ethnic labels that fail to capture the complex patterns of human genetic variation, the National Academies of Sciences, Engineering, and Medicine issued a report Tuesday calling for a transformation in how such descriptors are used. Read the rest…
Alphabet subsidiary and precision health company Verily recently announced a breakthrough in its AI drug discovery GPCR research collaboration with Sosei Heptares. Verily’s Immune Profiler platform is “a discovery engine consisting of proprietary immune profiling lab workflow, growing multi-omic database, and advanced analytical tools”.
Biotechnology, Pharma and Biopharma News – Research – Science – Lifescience ://Biotech-Biopharma-Pharma: Researchers develop an engineered ‘mini’ CRISPR genome editing system.The common analogy for CRISPR gene editing is that it works like molecular scissors, cutting out select sections of … Continue reading → (..)
The alliance will leverage the CRISPR genome editing technologies of Scribe to facilitate in genetic modification of new natural killer (NK) cell therapeutics for cancer. According to the deal, Sanofi will make an upfront payment of $25m to Scribe. Cell & Gene Therapy coverage on Pharmaceutical Technology is supported by Cytiva.
Biotechnology, Pharma and Biopharma News – Research – Science – Lifescience ://Biotech-Biopharma-Pharma: ERS Genomics and Cellular Engineering Technologies collaborating. from European Biotechnology – first and foremost in European biotech [link].
Presently, there are several companies and universities, which are exploring the potential of different gene editing technologies beyond CRISPR for basic research, and the development of gene editing solutions. Genome Editing is a way of making changes in the DNA. Genome Editing is a way of making changes in the DNA.
SAN FRANCISCO, CA—January 5, 2021—Over the past decade, the CRISPR genome-editing system has revolutionized molecular biology, giving scientists the ability to alter genes inside living cells for research or medical applications.
AAV genomes are highly compact, with overlapping coding regions, alternate splicing schemes, and multiple transcription initiation codons. There are two main genes in the AAV genome, rep and cap, which encode nine different proteins. Pfizer and Biogen stand in second and third positions, respectively.
Biotechnology, Pharma and Biopharma News – Research – Science – Lifescience ://Biotech-Biopharma-Pharma: ElevateBio cuts a deal for Life Edit, adding genomeengineering tech to support gene therapy pipeline.ElevateBio cuts a deal for Life Edit, adding genomeengineering tech to … Continue reading →
Genome editing is an exciting but still nascent field, and companies in the area face as many obstacles as they do opportunities. ZFPs can be engineered to make zinc finger nucleases, or ZFNs, which are proteins that can be used to edit genomes by knocking select genes in or out to specifically modify DNA sequences.
Researchers at the University of New Hampshire (UNH) have found that a repurposed drug, CCG-50014, could hinder the activity of a key enzyme of the SARS-CoV-2 virus, which causes Covid-19. Mpro has become the main focus of intense research and treatment development as it is vital for viral replication.
The new technologies will also overcome the manufacturing bottlenecks in delivering advanced engineered cell products. Its focus areas include human systems, precision diagnostics, data sciences, next-generation biomanufacturing, and genomic medicines.
To discover these associations, researchers need to compare the genomes of many individuals at millions of genetic locations or markers, and therefore require cost-effective genotyping technologies. A new statistical method, developed […].
LifeMine has developed an industrialised, genomics-based discovery engine that it hopes will take a broad, systematic approach to identifying new compounds from fungi and screening them for activity against disease targets. Image by jggrz from Pixabay .
CRISPR is notable for engineering living cells, allowing scientists to edit, turn off, delete, or replace genes in a cell’s genome. It is difficult to control where the viral vectors insert genes in the genome, and it is difficult to manufacture large quantities of clinical-grade viral vectors.
Moderna has entered a strategic research and development partnership with ElevateBio’s Life Edit Therapeutics to discover and develop new in-vivo mRNA gene editing therapies. Under the deal, both companies will partner on the research and preclinical studies, which will be funded by Moderna.
(NASDAQ: ILMN), the global leader in DNA sequencing and array-based technologies, and Sequoia Capital China , a leading investment firm, today announced a collaboration to catalyze the startup ecosystem in China with the launch of the Sequoia Capital China Intelligent Healthcare Genomics Incubator, Powered by Illumina.
DNA binding site prediction, peptide structure optimisation, and AI-assisted genome analysis are some of the accelerating innovation areas, where adoption has been steadily increasing. Codexis, a protein engineering company, is the leading patent filer.
Innovation S-curve for the pharmaceutical industry Gene splicing using nucleases is a key innovation area in the pharmaceutical industry Nucleases play a fundamental role in the field of recombinant DNA technology, or genetic engineering. Nucleases are enzymes that hydrolytically cleave the phosphodiester backbone of DNA.
Prevail will pay for research funding and tiered royalties on net future sales while Scribe will have the right to opt-in to co-fund and share profits in the US on a single collaboration programme from the latest partnership. “Our Scribe will receive $75m, including an upfront payment and equity investment via a convertible note.
Biotechnology, Pharma and Biopharma News – Research – Science – Lifescience ://Biotech-Biopharma-Pharma: Study reports six novel variants for CRISPR-Cas12a in plants, expanding genome engineering.In
Assessing clinical data across the lifespan identified the impact of genetic epilepsies on affected children’s lives Philadelphia, August 11, 2020 – A team of researchers at Children’s Hospital of Philadelphia (CHOP) affiliated with the CHOP Epilepsy Neurogenetics Initiative (ENGIN) further bridged the gap between genomic information (..)
Computational method capable of decoding influence of rare variants Geneticists could identify the causes of disorders that currently go undiagnosed if standard practices for collecting individual genetic information were expanded to capture more variants that researchers can now decipher, concludes new Johns Hopkins University research.
In a leap forward for immune privileged cell and organ therapy, researchers create first clinical xenotransplantation prototype with enhanced human immune compatibility and without active porcine endogenous retrovirus (PERV) Results published in Nature Biomedical Engineering demonstrate potential of Qihan’s genome … Continue reading → (..)
Credit: Scuba Zoo A study led by researchers at the Centre for Palaeogenetics in Stockholm shows that the last remaining populations of the Sumatran rhinoceros display surprisingly low levels of inbreeding.
Credit: LIU Yang Researchers from the Single-Cell Center at the Qingdao Institute of Bioenergy and Bioprocess Technology (QIBEBT) of the Chinese Academy of Sciences have developed a technique to sort and sequence the genome of bacteria in soil one bacterial cell at a time, while also identifying what its function is in the soil environment. […]. (..)
UMass Amherst epidemiologist serves as a leading researcher in global collaboration Credit: UMass Amherst By ensuring ethnic diversity in a largescale genetic study, an international team of researchers, including a University of Massachusetts Amherst genetic epidemiologist, has identified more regions of the genome linked to type 2 diabetes-related (..)
and OriCiro Genomics K.K. He continued: “OriCiro’s technology strategically complements our manufacturing expertise and further accelerates our research and development engine.”. Biotech Moderna, Inc. have announced they have entered into a definitive agreement for Moderna to acquire OriCiro at a cost of $85 million.
The Series B financing includes participation from all Series A investors and new investment from Fidelity Management & Research Company and T. There is also a functional genomics platform for novel target discovery. Rowe Price Associates, Inc., Rowe Price Associates, Inc., Odyssey Therapeutics’ founder and CEO, Gary D.
Early gene therapy methods were proposed in the 1970s, and the first approved gene therapy clinical research in the US began in 1990. New doors were opened in the 2000s with the development of genome editing, such as CRISPR-Cas9, which introduces molecular tools to change existing DNA. Collaboration and integrated manufacturing.
Assistant Professor Wei Xiong honored with inaugural CALPHAD Young Leader Award Credit: Wei Xiong PITTSBURGH (June 25, 2021) … CALPHAD (CALculation of PHAse Diagrams) is one of the genomic toolkits for material design and more recently is widely used in alloy innovation, ceramic design, processing optimization, and microstructure engineering.
International genomicsresearch led by the University of Leicester has used artificial intelligence (AI) to study an aggressive form of cancer, which could improve patient outcomes.
The CRISPR-based gene editor, C-to-G Base Editor (CGBE), opens up treatment avenues for up to 40 per cent of genetic disorders caused by single-nucleotide mutations Credit: Agency for Science, Technology and Research (A*STAR), Genome Institute of Singapore (GIS) A team of researchers from the Agency for Science, Technology and Research’s (A*STAR) (..)
Researchers at the University of California San Francisco (UCSF) and the Whitehead Institute have developed a novel CRISPR-based tool called “CRISPRoff” that can switch off genes in human cells through epigenetic editing without altering the genetic sequence itself. The research was published earlier this month in the journal Cell.
‘Exploring one of the biggest challenges facing genomics today – understanding genetic variants’ SEATTLE (February 22, 2021) – Global experts performing leading edge research in precision medicine, functional genomics, protein science, and variant interpretation and prediction will share their expertise and insights April 5-7 (..)
AstraZeneca’s rare disease firm Alexion is set to expand its genomic medicine portfolio with the acquisition of gene editing specialist LogicBio Therapeutics, in a deal worth approximately $68 million.
Researchers from Skoltech, Lomonosov Moscow State University, and the Kharkevich Institute for Information Transmission Problems have studied the genomes of some 200 strains of bacteria to determine which proteins in the ribosome, part of the key cell machinery, can be safely lost and why.
In the world of rare genetic diseases, exome and genome sequencing are two powerful tools used to make a diagnosis. A recent addition to the toolkit, RNA sequencing, has been demonstrated to help researchers narrow down disease candidate variants identified first on exome and genome sequencing.
Originally released in 1976, the NIH Guidelines for Research Involving Recombinant or Synthetic Nucleic Acid Molecules ( NIH Guidelines ) serve as the foundation of biosafety-focused oversight of research involving recombinant or synthetic nucleic acids (rsNA). Since then, however, certain genetic engineering technologies (e.g.,
We organize all of the trending information in your field so you don't have to. Join 21,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content